# Nanoviricides, Inc.: financial statements, quarterly

NNVC · NYSE · CIK 1379006 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/nnvc.md) · [Financials](/companies/nnvc/financials.md) · [Filings](/companies/nnvc/filings.md) · [Insiders](/companies/nnvc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nnvc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.0](/filings/0001410578-23-002484.md) | [0.0 d](/filings/0001410578-24-000048.md) | [0.0 d](/filings/0001410578-24-000843.md) | [0.0 d](/filings/0001410578-24-001650.md) | [0.0](/filings/0001410578-24-001991.md) | [0.0 d](/filings/0001410578-25-000140.md) | [0.0 d](/filings/0001410578-25-001336.md) | [0.0 d](/filings/0001104659-25-094527.md) | [0.0](/filings/0001104659-25-112608.md) | [0.0 d](/filings/0001104659-26-016476.md) | [0.0 d](/filings/0001104659-26-061499.md) | [0.0 d](/filings/0001104659-26-111390.md) |
| Research and development | $k | [1,467](/filings/0001410578-24-001991.md) | [1,574](/filings/0001410578-25-000140.md) | [1,215](/filings/0001410578-25-001336.md) | [1,182 d](/filings/0001104659-25-094527.md) | [1,933](/filings/0001104659-25-112608.md) | [1,156](/filings/0001104659-26-016476.md) | [1,282](/filings/0001104659-26-061499.md) | [1,177 d](/filings/0001104659-26-111390.md) | [993](/filings/0001104659-25-112608.md) | [1,119](/filings/0001104659-26-016476.md) | [1,286](/filings/0001104659-26-061499.md) | [1,310 d](/filings/0001104659-26-111390.md) |
| Operating income | $k | [(2,032)](/filings/0001410578-24-001991.md) | [(2,185)](/filings/0001410578-25-000140.md) | [(1,908)](/filings/0001410578-25-001336.md) | [(2,391) d](/filings/0001104659-25-094527.md) | [(3,168)](/filings/0001104659-25-112608.md) | [(2,059)](/filings/0001104659-26-016476.md) | [(2,249)](/filings/0001104659-26-061499.md) | [(2,116) d](/filings/0001104659-26-111390.md) | [(1,797)](/filings/0001104659-25-112608.md) | [(2,233)](/filings/0001104659-26-016476.md) | [(2,030)](/filings/0001104659-26-061499.md) | [(2,246) d](/filings/0001104659-26-111390.md) |
| Interest expense | $k | [36.5](/filings/0001410578-23-002484.md) | [13.3](/filings/0001410578-24-000048.md) | [0.0 d](/filings/0001410578-24-000843.md) | [0.0 d](/filings/0001104659-25-094527.md) | not reported | [0.1](/filings/0001104659-26-016476.md) | [0.0 d](/filings/0001104659-26-061499.md) | [0.0 d](/filings/0001104659-26-111390.md) | not reported | not reported | not reported | not reported |
| Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,969)](/filings/0001410578-25-001336.md) | [(2,115)](/filings/0001410578-25-001336.md) | [(1,854)](/filings/0001410578-25-001336.md) | [(2,356) d](/filings/0001104659-25-094527.md) | [(3,127)](/filings/0001104659-26-061499.md) | [(2,027)](/filings/0001104659-26-061499.md) | [(2,217)](/filings/0001104659-26-061499.md) | [(2,096) d](/filings/0001104659-26-111390.md) | [(1,785)](/filings/0001104659-26-061499.md) | [(2,221)](/filings/0001104659-26-061499.md) | [(1,989)](/filings/0001104659-26-061499.md) | [(2,223) d](/filings/0001104659-26-111390.md) |
| Diluted EPS | $ per share | [(0.17)](/filings/0001410578-24-001991.md) | [(0.18)](/filings/0001410578-25-000140.md) | [(0.16)](/filings/0001410578-25-001336.md) | not reported | [(0.23)](/filings/0001104659-25-112608.md) | [(0.14)](/filings/0001104659-26-016476.md) | [(0.14)](/filings/0001104659-26-061499.md) | not reported | [(0.10)](/filings/0001104659-25-112608.md) | [(0.11)](/filings/0001104659-26-016476.md) | [(0.09)](/filings/0001104659-26-061499.md) | not reported |
| Basic EPS | $ per share | [(0.17)](/filings/0001410578-24-001991.md) | [(0.18)](/filings/0001410578-25-000140.md) | [(0.16)](/filings/0001410578-25-001336.md) | not reported | [(0.23)](/filings/0001104659-25-112608.md) | [(0.14)](/filings/0001104659-26-016476.md) | [(0.14)](/filings/0001104659-26-061499.md) | not reported | [(0.10)](/filings/0001104659-25-112608.md) | [(0.11)](/filings/0001104659-26-016476.md) | [(0.09)](/filings/0001104659-26-061499.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.0](/filings/0001410578-23-002484.md) | [5.2](/filings/0001410578-24-000048.md) | [3.3](/filings/0001410578-24-000843.md) | [4.8](/filings/0001104659-25-094527.md) | [3.9](/filings/0001410578-24-001991.md) | [4.0](/filings/0001410578-25-000140.md) | [2.5](/filings/0001410578-25-001336.md) | [1.6](/filings/0001104659-26-111390.md) | [1.1](/filings/0001104659-25-112608.md) | [5.2](/filings/0001104659-26-016476.md) | [3.2](/filings/0001104659-26-061499.md) | [2.8](/filings/0001104659-26-111390.md) |
| Current assets | $m | [7.1](/filings/0001410578-23-002484.md) | [5.3](/filings/0001410578-24-000048.md) | [3.5](/filings/0001410578-24-000843.md) | [5.0](/filings/0001104659-25-094527.md) | [4.0](/filings/0001410578-24-001991.md) | [4.1](/filings/0001410578-25-000140.md) | [2.7](/filings/0001410578-25-001336.md) | [1.7](/filings/0001104659-26-111390.md) | [1.3](/filings/0001104659-25-112608.md) | [5.3](/filings/0001104659-26-016476.md) | [3.4](/filings/0001104659-26-061499.md) | [3.2](/filings/0001104659-26-111390.md) |
| Total assets | $m | [15.4](/filings/0001410578-23-002484.md) | [13.4](/filings/0001410578-24-000048.md) | [11.5](/filings/0001410578-24-000843.md) | [12.8](/filings/0001104659-25-094527.md) | [11.7](/filings/0001410578-24-001991.md) | [11.6](/filings/0001410578-25-000140.md) | [10.0](/filings/0001410578-25-001336.md) | [8.8](/filings/0001104659-26-111390.md) | [8.4](/filings/0001104659-25-112608.md) | [12.3](/filings/0001104659-26-016476.md) | [10.2](/filings/0001104659-26-061499.md) | [9.9](/filings/0001104659-26-111390.md) |
| Current liabilities | $m | [0.9](/filings/0001410578-23-002484.md) | [1.0](/filings/0001410578-24-000048.md) | [0.8](/filings/0001410578-24-000843.md) | [1.4](/filings/0001104659-25-094527.md) | [1.6](/filings/0001410578-24-001991.md) | [1.2](/filings/0001410578-25-000140.md) | [1.2](/filings/0001410578-25-001336.md) | [1.3](/filings/0001104659-26-111390.md) | [1.2](/filings/0001104659-25-112608.md) | [1.2](/filings/0001104659-26-016476.md) | [1.1](/filings/0001104659-26-061499.md) | [1.2](/filings/0001104659-26-111390.md) |
| Total liabilities | $m | [2.4](/filings/0001410578-23-002484.md) | [1.0](/filings/0001410578-24-000048.md) | [0.8](/filings/0001410578-24-000843.md) | [1.4](/filings/0001410578-24-001650.md) | [1.6](/filings/0001410578-24-001991.md) | [1.2](/filings/0001410578-25-000140.md) | not reported | [1.3](/filings/0001104659-25-094527.md) | [1.2](/filings/0001104659-25-112608.md) | [1.2](/filings/0001104659-26-016476.md) | [1.1](/filings/0001104659-26-061499.md) | [1.2](/filings/0001104659-26-111390.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [13.0](/filings/0001410578-25-001336.md) | [12.5](/filings/0001410578-25-001336.md) | [10.7](/filings/0001410578-25-001336.md) | [11.5](/filings/0001104659-26-111390.md) | [10.1](/filings/0001104659-26-061499.md) | [10.4](/filings/0001104659-26-061499.md) | [8.8](/filings/0001104659-26-061499.md) | [7.5](/filings/0001104659-26-111390.md) | [7.2](/filings/0001104659-26-061499.md) | [11.1](/filings/0001104659-26-061499.md) | [9.2](/filings/0001104659-26-061499.md) | [8.7](/filings/0001104659-26-111390.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,172)](/filings/0001410578-24-001991.md) | [(1,719) d](/filings/0001410578-25-000140.md) | [(1,944) d](/filings/0001410578-25-001336.md) | [(1,481) d](/filings/0001104659-25-094527.md) | [(2,595)](/filings/0001104659-25-112608.md) | [(2,191) d](/filings/0001104659-26-016476.md) | [(1,991) d](/filings/0001104659-26-061499.md) | [(1,702) d](/filings/0001104659-26-111390.md) | [(1,594)](/filings/0001104659-25-112608.md) | [(2,050) d](/filings/0001104659-26-016476.md) | [(1,931) d](/filings/0001104659-26-061499.md) | [(2,122) d](/filings/0001104659-26-111390.md) |
| Capital expenditure | $k | [8.3](/filings/0001410578-24-001991.md) | [5.5 d](/filings/0001410578-25-000140.md) | [44.6 d](/filings/0001410578-25-001336.md) | [98.2 d](/filings/0001104659-25-094527.md) | [46.8](/filings/0001104659-25-112608.md) | [0.0 d](/filings/0001104659-26-016476.md) | [0.0 d](/filings/0001104659-26-061499.md) | [10.2 d](/filings/0001104659-26-111390.md) | [84.3](/filings/0001104659-25-112608.md) | [(0.0) d](/filings/0001104659-26-016476.md) | [0.0 d](/filings/0001104659-26-061499.md) | [0.0 d](/filings/0001104659-26-111390.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [11.6](/filings/0001410578-23-002484.md) | [11.6](/filings/0001410578-24-000048.md) | [11.6](/filings/0001410578-24-000843.md) | [11.7](/filings/0001410578-24-001991.md) | [11.7](/filings/0001410578-25-000140.md) | [11.8](/filings/0001410578-25-001336.md) | [13.7](/filings/0001104659-25-112608.md) | [14.6](/filings/0001104659-26-016476.md) | [16.0](/filings/0001104659-26-061499.md) | [17.1](/filings/0001104659-25-112608.md) | [19.9](/filings/0001104659-26-016476.md) | [21.6](/filings/0001104659-26-061499.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 25,525,000 at 2026-09-28, from the cover of the [10-K filed 2026-09-28](/filings/0001104659-26-111390.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.